title: A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens.
abstract: OBJECTIVE
  Many hepatitis C virus regimens are unlikely to be compared head to head. In more difficult to treat populations where there is no standard of care, trials are single arm. We describe a flexible meta-analysis platform in this setting.
  
  
  METHODS
  Our meta-analysis is literature based. We illustrate our methodology and show how inference can be extended to single-arm trials.
  
  
  RESULTS
  As an example, in the single arm setting, a regimen with response rates of 84, 72 and 54% in genotype 1a across treatment naive, previous partial responders and previous null responders, respectively, would have 95% probability of superiority to IFN-α + RBV + TPV.
  
  
  CONCLUSIONS
  This is a rigorous approach to comparative effectiveness that accounts for varying patient populations and plans for the incorporation of emerging treatments.
authors.affiliation: Berry Consultants, LLC, Austin, TX 78746, USA.
authors.forename: Kristine R
authors.initials: KR
authors.lastname: Broglio
authors.forename: Eric S
authors.initials: ES
authors.lastname: Daar
authors.forename: Melanie
authors.initials: M
authors.lastname: Quintana
authors.forename: Yong
authors.initials: Y
authors.lastname: Yuan
authors.forename: Anupama
authors.initials: A
authors.lastname: Kalsekar
authors.forename: Brad
authors.initials: B
authors.lastname: Spellberg
authors.forename: Roger J
authors.initials: RJ
authors.lastname: Lewis
authors.forename: Dan van den
authors.initials: Dv
authors.lastname: Akker
authors.forename: Michelle A
authors.initials: MA
authors.lastname: Detry
authors.forename: Trong
authors.initials: T
authors.lastname: Le
authors.forename: Scott M
authors.initials: SM
authors.lastname: Berry
mesh_terms: D000465:Algorithms; D000998:Antiviral Agents / Q000627:therapeutic use*; D001499:Bayes Theorem; D057186:Comparative Effectiveness Research; D004359:Drug Therapy, Combination; D016174:Hepacivirus; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D009842:Oligopeptides / Q000627:therapeutic use*; D011392:Proline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D009842:Oligopeptides; D012254:Ribavirin; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline
keywords: Bayesian hierarchical model; boceprevir; comparative effectiveness; hepatitis C; meta-analysis; sustained virologic response; telaprevir